<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731376</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001062</org_study_id>
    <secondary_id>NCI-2020-06998</secondary_id>
    <secondary_id>EU5097-20</secondary_id>
    <secondary_id>P30CA138292</secondary_id>
    <nct_id>NCT04731376</nct_id>
  </id_info>
  <brief_title>Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone</brief_title>
  <official_title>Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial investigates the safety of testosterone replacement therapy around the&#xD;
      time of major urologic surgery (perioperative) in order to improve quality of life and&#xD;
      post-operative outcomes such as decreased length of hospital stay, complications, and&#xD;
      mortality in patients with low testosterone levels. Studies have demonstrated that patients&#xD;
      undergoing testosterone replacement therapy have increased lean body mass, decreased fat mass&#xD;
      and have improved physical function. Testosterone replacement therapy can also stimulate bone&#xD;
      formation and may decrease the risk of fracture. Information from this trial may be used to&#xD;
      support the incorporation of testosterone level testing and testosterone replacement into the&#xD;
      perioperative treatment decision-making process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To examine the safety and feasibility of perioperative testosterone replacement (TR)&#xD;
      therapy in hypogonadal male patients undergoing major operations.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients with low testosterone levels receive testosterone cypionate intramuscularly&#xD;
      (IM) once a week (QW) for 3 months in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM II: Patients with normal testosterone levels receive standard peri-operative care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in quality of life before and after surgery</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>The Patient Reported Outcomes Measurement Information System (PROMIS Global Health-10) is a 10 question survey that uses questions concerning physical function, overall quality of life, physical health, mood, ability to participate in social roles and activities, pain and fatigue to arrive at a score between 10 and 50. Patient's score are the outcome we will measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in frailty phenotype before and after surgery</measure>
    <time_frame>Baseline, post operative refers to the period after the procedure until final follow up and study completion. Will occur an average of 90 days after the procedure.</time_frame>
    <description>The Fried Frailty Criteria uses a comorbidity scale, measures of activity, physical tests of strength and speed, nutritional status and anatomic features to produce a score from 0-5. These numbers correspond with the following frailty categorizations: non-frail (score 0), pre-frail (score 1-2) and frail (score 3-5). This score represents one outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major complications</measure>
    <time_frame>Within 90 days of surgery</time_frame>
    <description>Major complication considered Clavien-Dindo IIIb and above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minor complications</measure>
    <time_frame>Within 90 days of surgery</time_frame>
    <description>Minor complication considered Clavien-Dindo IIIb and below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of intensive care unit (ICU) admission</measure>
    <time_frame>Up to 3 months post-surgery</time_frame>
    <description>Admissions to the ICU between post-op day 1 to 90 days post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 3 months post-operative</time_frame>
    <description>Number of days stayed in the hospital after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discharge disposition</measure>
    <time_frame>Discharge from hospital</time_frame>
    <description>Determined by if patient is discharged to home, to home with services, or to facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unplanned readmissions</measure>
    <time_frame>Within 90 days of surgery</time_frame>
    <description>Readmissions to hospital after discharge within 90 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Within 90 days of surgery</time_frame>
    <description>Rate of patient deaths after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testosterone level</measure>
    <time_frame>Up to 3 months post-operative</time_frame>
    <description>Levels of Testosterone determined by laboratory blood draw</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Malignant Urinary System Neoplasm</condition>
  <condition>Urinary System Disorder</condition>
  <condition>Urinary System Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (testosterone cypionate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (best practice)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with normal testosterone levels receive standard peri-operative care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive standard peri-operative care</description>
    <arm_group_label>Arm II (best practice)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (testosterone cypionate)</arm_group_label>
    <arm_group_label>Arm II (best practice)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (testosterone cypionate)</arm_group_label>
    <arm_group_label>Arm II (best practice)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Cypionate</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (testosterone cypionate)</arm_group_label>
    <other_name>depAndro</other_name>
    <other_name>Depo-Testosterone</other_name>
    <other_name>Depotest</other_name>
    <other_name>Depovirin</other_name>
    <other_name>Pertestis</other_name>
    <other_name>Virilon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients already scheduled for major surgery requiring an overnight hospital stay&#xD;
&#xD;
          -  Patients must be able to give informed consent&#xD;
&#xD;
          -  Patients must be willing to do study's preoperative and post-operative assessment&#xD;
             tools&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with history of prostatectomy with detectable prostate specific antigen (PSA)&#xD;
&#xD;
          -  Patient with history of prostate radiation/chemotherapy treatment and has experienced&#xD;
             bounce or rise in PSA&#xD;
&#xD;
          -  Patients with history of/undergoing orchiectomy&#xD;
&#xD;
          -  Patients undergoing hormone replacement therapy currently or history of testosterone&#xD;
             use within last year&#xD;
&#xD;
          -  Patients who use anabolic steroids&#xD;
&#xD;
          -  Patients who are undergoing chemotherapy and/or radiation therapy pre- or&#xD;
             post-operatively&#xD;
&#xD;
          -  Patients with history of solitary or undescended testis&#xD;
&#xD;
          -  Patients with history of pituitary disorders&#xD;
&#xD;
          -  Patients with history of thromboembolic events in last year&#xD;
&#xD;
          -  Patients with hematocrit &gt; 55%&#xD;
&#xD;
          -  Patients with uncontrolled congestive heart failure&#xD;
&#xD;
          -  Special populations: Adults unable to consent, individuals who are not yet adults&#xD;
             (infants, children, teenagers), pregnant women and prisoners&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Ogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital/Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Ogan, MD</last_name>
    <phone>404-778-3038</phone>
    <email>kogan@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mersiha Torlak</last_name>
      <phone>404-778-4823</phone>
      <email>mersiha.torlak@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Ogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kenneth Ogan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

